Phase 2 Study: L-SABR Plus Standard Therapy in Metastatic NSCLC Patients
Photo by CNordic Nordic / Unsplash
Key Takeaway
Consider L-SABR in metastatic NSCLC; results pending for progression-free survival impact.
This ongoing Phase 2 trial, sponsored by Memorial Sloan Kettering Cancer Center, investigates the efficacy of adding liver stereotactic ablative radiotherapy (L-SABR) to standard drug therapy, which includes anti-PD-(L)1 based immunotherapy and platinum-based chemotherapy, in patients with metastatic non-small cell lung cancer (NSCLC). The study aims to enroll 68 participants, with a primary endpoint of median progression-free survival. The trial began on December 9, 2022, and is expected to reach primary completion by December 9, 2026. Secondary endpoints and safety data will be evaluated, but specific results and statistical analyses are not yet available. Clinicians should consider the potential of L-SABR as an adjunctive treatment in metastatic NSCLC pending further data.
More on Non-Small Cell Lung Cancer
Benmelstobart plus anlotinib improves progression-free survival versus pembrolizumab plus placebo in first-line PD-L1-positive advanced NSCLC.
New drug combo may extend time before cancer grows in lung patients
This randomised, controlled, phase 3 trial evaluated benmelstobart plus anlotinib versus pembrolizumab plus placebo in patients with PD-L1-p…
A new drug combo may extend the time before cancer grows in lung patients who have not yet received treatment for their advanced disease.
Phase 3 trial of pembrolizumab versus placebo after surgery for Stage IB-IIIA NSCLC posts results
Can a drug help keep lung cancer from returning after surgery?
A Phase 3 randomized controlled trial in 1177 participants with resected Stage IB-IIIA NSCLC compared adjuvant pembrolizumab to placebo. The…
A large trial tested whether the drug pembrolizumab helps keep early-stage lung cancer from returning after surgery for over 1,100 patients.
Phase III trial tests TTFields plus standard therapy for stage 4 NSCLC after platinum failure
Can adding electric fields to standard treatment help people with advanced lung cancer?
A prospective, randomized phase III trial in 291 patients with stage 4 NSCLC after platinum progression compared TTFields plus standard ther…
Doctors are testing if adding a wearable electric field device to standard drugs helps people with advanced lung cancer live longer after ch…
Phase 2 trial of neoadjuvant/adjuvant pembrolizumab in stage IB-IIIA NSCLC completes enrollment of 35 patients
Can immunotherapy before lung cancer surgery help the immune system fight the tumor?
A multi-institutional phase 2 trial has completed enrollment of 35 patients to study neoadjuvant and adjuvant pembrolizumab in stage IB, II,…
Doctors tested giving immunotherapy before lung cancer surgery to see if it safely boosts the immune system's ability to fight the tumor.
View Original Abstract ↓
Status: RECRUITING | Phase: PHASE2
Condition(s): Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma, NSCLC, NSCLC Stage IV
Intervention(s): L-SABR (RADIATION), Anti-PD-(L)1 based immunotherapy (BIOLOGICAL), Platinum based chemotherapy (DRUG)
The purpose of this study is to see whether adding liver stereotactic ablative radiotherapy/L-SABR to standard drug therapy is better than standard drug therapy alone for people with metastatic non-small cell lung cancer/NSCLC.
Primary Outcome(s): Median progression-free survival
Enrollment: 68 (ESTIMATED)
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Start: 2022-12-09 | Primary Completion: 2026-12-09
Prophylactic rhG-CSF with platinum chemotherapy improves immune markers and response rates in advanced lung cancer patients.
New drug boost may help some advanced lung cancer patients respond better to treatment
Related in Pulmonology & Critical Care
Review of CFTR modulator impact on cystic fibrosis outcomes from registry data
Cystic Fibrosis Patients See Lung Function Jump Over a Decade
This review and synthesis of Cystic Fibrosis Foundation Patient Registry data describes trends in adults with cystic fibrosis from 2011 to 2…
A decade of registry data shows lung function and weight improved for adults with cystic fibrosis as newer modulator therapies became availa…
Pulmonary barotrauma incidence and risk factors in non-HIV PCP patients
Researchers find oxygen ratio predicts lung injury in pneumonia patients
This single-center retrospective cohort study of 334 non-HIV patients with Pneumocystis jirovecii pneumonia found that 12.0% developed pulmo…
A new model helps identify pneumonia patients at higher risk for severe lung complications using oxygen levels and blood markers.
LSTM analysis of infant tidal breathing detects bronchopulmonary dysplasia with 97% accuracy
New AI tool reads baby breath to spot lung disease early
This cohort study of 329 infants and 135 school-age children used recurrent neural networks to analyze tidal breathing flow time series. The…
A new computer model can read a baby's simple breathing pattern to find lung disease before it becomes serious.
Review synthesizes pilot data on nasal microbiota and respiratory outcomes in infants
Nasal bacteria clues could predict infant wheezing risks early
This review synthesizes findings from a pilot observational study involving 55 infants enrolled in the AERIAL study. The authors examine nas…
Specific nose bacteria might predict wheezing risks for babies during their first year of life soon enough now.
From Other Specialties
Nicotinic partial agonists show no effect on opioid use in HIV-positive smokers
New data on nicotine treatment for HIV patients who use opioids
This secondary analysis of a randomized trial in 97 HIV-positive smokers with risky alcohol use and baseline opioid use found no significant…
A new look at nicotine treatment for HIV patients who use opioids found no difference in opioid use between two drug groups.
CRS3123 shows efficacy in phase 2 trial for Clostridioides difficile infection
Early trial shows CRS3123 matches vancomycin for treating C. diff infection
This phase 2 randomized trial compared CRS3123 with vancomycin in 43 adults with CDI. Clinical cure rates were similar across groups, but re…
A small Phase 2 trial found CRS3123 worked as well as vancomycin for curing C. diff infection in adults with their first episode or recurren…
Valacyclovir No Better Than Placebo for Stromal Keratitis in Herpes Zoster Ophthalmicus
Oral antivirals do not prevent eye inflammation in shingles patients
This secondary analysis of a randomized trial in 527 patients with herpes zoster ophthalmicus found that oral valacyclovir 1 g daily did not…
A study of 527 people with shingles eye infections found oral antivirals did not stop inflammation. Close monitoring and low-potency steroid…
Positive in vitro interactions with β-lactam linked to lower 14-day mortality in MRSA bacteraemia
Positive lab interactions linked to lower early death in MRSA infection treatment
This post hoc analysis of a multicentre randomized trial included 150 adults with MRSA bacteraemia. Positive in vitro interactions between v…
When lab tests showed bacteria died better with combined drugs, patients had lower early death rates. This finding suggests smarter drug pai…